Drug Profile
BNT 114
Alternative Names: BNT-114; IVAC W bre1 uID; IVAC_W_bre1_uIDLatest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator BioNTech
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for phase-I development in Triple negative Breast-cancer(Combination therapy) in Germany (Parenteral, Injection)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Triple negative Breast-cancer(Combination therapy) in Sweden (Parenteral, Injection)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Triple negative Breast-cancer(Monotherapy) in Germany (Parenteral, Injection)